Lilly liver cancer drug fails Phase 3 trial

In a Phase 3 study, Eli Lilly's (LLY) orphan drug-designated liver cancer product candidate Cyramza (ramucirumab) failed to meet its primary endpoint of a statistically significant improvement in overall survival (OS). The trial compared Cyramza plus best supportive care to placebo plus best supportive care as a second-line treatment in patients with hepatocellular carcinoma (HCC) after being treated with sorafenib as a first-line therapy.

SVP, Product Development and Medical Affairs for Lilly Oncology, Richard Gaynor, M.D., says, "Although the REACH study did not achieve statistical significance for survival, we are encouraged by the efficacy seen overall, especially in specific subpopulations. We plan to discuss these results with regulatory authorities."

From other sites
Comments (3)
    , contributor
    Comments (19) | Send Message
    Lilly needs a break. Mostly me too
    11 Jun 2014, 09:37 AM Reply Like
  • Siwanoy
    , contributor
    Comments (717) | Send Message
    Recently the stock appears to trade down all day by a not insignificant amount and then turns green before close. Either there is a betting limit to their trouble or Flash Boys are at it. At least they paid their dividend.
    11 Jun 2014, 09:47 AM Reply Like
    , contributor
    Comments (19) | Send Message
    Well, I think there are some games being plaid. A while ago, they submitted arzoxifene to the FDA right before a quarterly earnings call and then withdrew it right after the quarterly earnings call. This looked like one executives decision who I think is no longer with that company
    16 Jun 2014, 09:40 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs